875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants

BACKGROUND: Switching to cabotegravir long-acting + rilpivirine long-acting (CAB LA + RPV LA) administered every month (Q1M) has demonstrated non-inferiority in viral suppression versus a range of standard of care (SoC) antiretroviral regimens, including tenofovir alafenamide based regimens, in two...

Descripción completa

Detalles Bibliográficos
Autores principales: Snedecor, Sonya J, Schroeder, Melanie, Van de Velde, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644599/
http://dx.doi.org/10.1093/ofid/ofab466.1070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644599/
http://dx.doi.org/10.1093/ofid/ofab466.1070

Ejemplares similares